Best multivitamin for men over 60: what the trials tested

Older man with a grey beard in profile against a black background

The best multivitamin for men over 60 is a plain, broad-spectrum daily multivitamin-mineral with no iron, B12 in its free supplement form, and at least 800 IU of vitamin D. That is close to what the big randomised trials in older adults actually tested: an ordinary, off-the-shelf daily multi taken for years. None of those trials tested a megadose formula.

That matters because 60 is where the evidence finally exists. The biggest multivitamin trials were run in older people, so a man of 62 can read actual trial results instead of guessing from a tub that says "50+" on the front. The results are mixed, and the mix is useful.

The short version

Where the "senior formula" idea comes from

Age-banded multivitamins sell because they feel right. You are older, so surely you need a different product. The official numbers barely move. In the Institute of Medicine's 2011 review, the vitamin D RDA steps from 600 IU to 800 IU a day at age 71. That is the whole change for vitamin D, and it lands a decade after 60.

What changes after 60 is absorption, and the pills you already take. Stomach acid falls with age, which makes the B12 in food harder to release. Baik and Russell estimated B12 deficiency at 10 to 15 percent of people over 60, and found that absorption of crystalline B12, the free form used in supplements, stays intact even when stomach acid is low. We went through the stomach-acid side of this in the guide for men over 50, so we won't repeat it here.

Muscle is the other shift, and no multivitamin covers it. The PROT-AGE group recommends people over 65 eat at least 1.0 to 1.2g of protein per kilo of body weight a day, more if they train. A scoop of anything is a footnote next to that.

What the trials in older men actually found

Two large randomised programmes have tested a daily multivitamin against placebo in older people. Both used an ordinary commercial multi. Here is what they reported.

Study Who Length Result
PHS II, cancer 14,641 male doctors aged 50+, mean age 64 Median 11.2 years 8% fewer total cancers (HR 0.92), no effect on prostate cancer
PHS II, heart The same 14,641 men Median 11.2 years No effect on major cardiovascular events (HR 1.01)
PHS II, cognition 5,947 men aged 65+ Up to 12 years No difference in cognitive change
COSMOS, cancer and heart 21,442 adults (men 60+, women 65+) Median 3.6 years No effect on total cancer (HR 0.97) or cardiovascular events (HR 0.98)
COSMOS, cognition meta-analysis 5,203 adults across 3 substudies 2 to 3 years Better global cognition and memory, about 2 years less cognitive ageing

Cancer: one small yes, one no

PHS II is the longest trial of its kind. Men on the multivitamin had 17.0 cancers per 1,000 person-years against 18.3 on placebo, a hazard ratio of 0.92. It was statistically significant, and the upper end of the confidence interval was 0.998, which is about as close to no effect as a significant result gets.

COSMOS ran for a median of 3.6 years and found no significant effect on total invasive cancer. A secondary result showed fewer lung cancers (HR 0.62). Secondary results are where trials go to generate the next question, so treat that one as interesting and nothing more.

Heart: nothing, twice

PHS II found no effect on heart attack, stroke or cardiovascular death over 11 years. COSMOS found the same thing over 3.6. If a multivitamin is being sold to you as heart protection after 60, the two biggest trials disagree.

Memory: the newest data, and the most interesting

The older trial said no. In PHS II, 5,947 men aged 65 and over showed no cognitive difference after up to 12 years, and the authors noted their doctors may have been too well-nourished to benefit.

COSMOS said yes, modestly. COSMOS-Mind followed 2,262 people with a mean age of 73 and found a significant benefit on global cognition over 3 years. COSMOS-Web tested 3,562 older adults online and estimated the memory improvement at the equivalent of 3.1 years of age-related memory change. Pooling three substudies, the COSMOS meta-analysis put the effect at roughly 2 years less cognitive ageing.

Small effects. Real ones, in a randomised design, in exactly the age group reading this.

Living longer: no signal

The biggest observational look, 390,124 US adults followed for up to 27 years, found daily multivitamin use was not linked to lower mortality. People who take multivitamins tend to be healthier in the first place, which makes this kind of data hard to read in either direction, but nobody should buy a multi expecting extra years.

What this means when you choose one

Put the trials together and the checklist gets short.

Then the bigger levers: protein at the PROT-AGE level, resistance training, and a blood test before you assume a supplement is the answer to anything.

Where Fireblood fits, honestly

Fireblood was not the product in any of these trials. Nobody has run a trial of our formula in men over 60, and we are not going to borrow results that belong to someone else's tablet.

What we can show you is how it lines up against the checklist. No iron. 2,000 IU of vitamin D3. B12 as methylcobalamin at 2.5ug, which sits just over the 2.4mcg RDA. That is a maintenance amount. If you have been on metformin or an acid blocker for years, or your bloods have come back low, a multivitamin is the wrong tool and that is a conversation with your GP.

It also contains 120ug of vitamin K1 and 120ug of K2. So if you take warfarin, Fireblood is one to clear with your doctor first, the same as any multi with vitamin K in it. And it carries all nine essential amino acids including 992mg of leucine, which helps a little with the protein problem and does not replace a single meal.

At 60, read the iron line and the vitamin K line before you read anything else on the tub.

Fireblood is 39 ingredients in one scoop: no iron, 2,000 IU of D3, methylcobalamin B12, bisglycinate minerals and all nine essential amino acids. The full label, doses included, is on the product page.

Image: Old Man by Graham Crumb, CC BY-SA 3.0, via Wikimedia Commons.